OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 331 participants.
Also called NCT01182493
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 331 participants
- Sponsor
- Registry
-
NCT01182493
-
- Other papers using this trial's data
- Complex Assessment of Metabolic Effectiveness of Insulin Pump Therapy in Patients with Type 2 Diabetes Beyond HbA1c Reduction
- Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial
- Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Austria, Canada, France, Germany, Hungary, Israel, Italy, Netherlands, North Macedonia, Serbia, South Africa, Spain
- Registry status
- Completed
Technical summary
Registry record NCT01182493. Randomized; no masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2016-03-15.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- OpT2mise Glucose Control in Type 2 Diabetes Mellitus (DM) With Insulin Pump Therapy
- Acronym
- OpT2mise
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Device)
- Insulin Pump (Medtronic Minimed Paradigm® VEO)
- Lead sponsor
- Medtronic MiniMed, Inc.
Record details
- Record id
cardio:ct-nct01182493- Content hash
1f911913b9896fe807b7e5549e6fc482c426b65460d5e14bb45b2256fb8cf971